SIC
BLUE

Samalin Investment Counsel’s bluebird bio BLUE Stock Holding History

Samalin Investment Counsel’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-89
Closed -$100K – 184
2019
Q4 		$100K Buy
+89
New +$96.7K 0.08% 226

Other funds holding BLUE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Samalin Investment Counsel's BLUE Position: Q1 2020 in Review

Samalin Investment Counsel sold out of bluebird bio (BLUE) in Q1 2020, closing a stake of 89 shares — an estimated $100K sold.

Samalin Investment Counsel first reported a position in BLUE in Q4 2019 and held it in 1 quarter. The position peaked at $100K in Q4 2019. 247 funds tracked by Wall St. Rank hold BLUE as of Q1 2020.

  • Samalin Investment Counsel reported no remaining bluebird bio position as of Q1 2020 after selling out during the quarter.
  • Samalin Investment Counsel sold 89 bluebird bio shares in Q1 2020, an estimated $100K.
  • Samalin Investment Counsel first reported a position in bluebird bio in Q4 2019 and held it in 1 quarter.
  • Samalin Investment Counsel's bluebird bio position peaked at $100K in Q4 2019.
  • 247 funds tracked by Wall St. Rank held bluebird bio as of Q1 2020.

Based on Samalin Investment Counsel's 13F filing for Q1 2020, filed 4 May 2020.